SCHEMBL6438149

SCHEMBL6438149

Nc1ncnc2c1c(-c1ccc(Oc3ccccc3)cc1)nn2C1CN(C(=O)CN2CCOCC2)C1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BTK Q06187 20/20 0.70
EGFR P00533 7/20 0.70
LCK P06239 4/20 0.70
ITK Q08881 4/20 0.70
JAK3 P52333 2/20 0.70
FLT3 P36888 2/20 0.64
KIT P10721 1/20 0.64
TEC P42680 3/20 0.62
BMX P51813 3/20 0.62
TXK P42681 2/20 0.62
LYN P07948 2/20 0.62
FGFR2 P21802 2/20 0.62
RIPK2 O43353 1/20 0.62
NR1I2 O75469 1/20 0.62
SLC22A3 O75751 1/20 0.62
LATS1 O95835 1/20 0.62
NUDT14 O95848 1/20 0.62
ABL1 P00519 1/20 0.62
ERBB2 P04626 1/20 0.62
FYN P06241 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Morpholine SCHEMBL7141268 0.95 BTK (0.65) BTKEGFRLCKITKJAK3
SCHEMBL5802021 0.94 BTK (0.67) BTKEGFRLCKITKJAK3
SCHEMBL17951506 0.93 BTK (0.79) BTKEGFRLCKITKJAK3
SCHEMBL19649357 0.93 BTK (0.79) BTKEGFRLCKITKJAK3
SCHEMBL17951522 0.93 BTK (0.77) BTKEGFRLCKITKJAK3
Acetic Acid SCHEMBL6433269 0.91 BTK (0.74) BTKEGFRLCKITKJAK3
SCHEMBL6460065 0.90 BTK (0.69) BTKEGFRLCKITKJAK3
SCHEMBL6433637 0.90 BTK (0.68) BTKEGFRLCKITKJAK3
SCHEMBL6430327 0.89 BTK (0.68) BTKEGFRLCKITKJAK3
SCHEMBL6432745 0.89 BTK (0.64) BTKEGFRLCKITKJAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6921763-B2 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2005-07-26 US disclosed
US-20050008640-A1 Method of treating transplant rejection ABBOTT LABORATORIES 2005-01-13 US disclosed
EP-1212327-B1 PYRAZOLOPYRIMIDINES AS THERAPEUTIC AGENTS BASF AG (DE) 2003-08-20 EP disclosed
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents ABBOTT LABORATORIES (US) 2002-10-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050008640-A1 Method of treating transplant rejection LCK, ZAP70, FYN BTK 42/4885EGFR 818/4885LCK 1/4885
US-20020156081-A1 Pyrazolopyrimidines as therapeutic agents DPYD, CYP2D6, UGT1A1 BTK 1020/4885EGFR 2229/4885LCK 1011/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.